Trial ID or NCT#

NCT00725946

Status

NOT RECRUITING

Purpose

This is a pilot imaging study for women whose tumors express NIS [Na+I- symporter, sodium iodide symporter]. Eligibility is limited to the presence of strong (3+) and/or plasma membrane staining in > 20% of cells as determined by immunohistochemical methods. A total of 10 patients will be imaged with 124I PET/CT (serial scans over 24 hour period) to determine radioiodide uptake and distribution in tumor tissue. Thyroid iodide uptake and retention will be blocked beginning one week prior to 124I PET/CT scan with thyroid hormone (T3) and methimazole (impedes organification). Tumor, organ and whole body dosimetry will be calculated in each patient.

Official Title

A Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: Female
Accepts Healthy Volunteers: No

Investigator(s)

Laurence Katznelson, MD
Neuroendocrinologist
Professor of Neurosurgery and of Medicine (Endocrinology) at the Stanford University Medical Center, Lucile Salter Packard Children's Hospital and at the Palo Alto Veterans Affairs Health Care System
Iris C. Gibbs, MD, FACR
Radiation oncologist, Neuro-oncologist
Professor of Radiation Oncology (Radiation Therapy) at the Stanford University Medical Center
Sanjiv Sam Gambhir, MD, PhD
Lawrence Recht, MD
Neuro-oncologist
Professor of Neurology and, by courtesy, of Neurosurgery at the Stanford University Medical Center
Michael L. Goris
Robert W. Carlson

Contact us to find out if this trial is right for you.

CONTACT

Marilyn Florero
(650) 724-1953